Pharma Mar SA
OTC:PHMMF

Watchlist Manager
Pharma Mar SA Logo
Pharma Mar SA
OTC:PHMMF
Watchlist
Price: 90.21 USD
Market Cap: 1.6B USD

Operating Margin

12.3%
Current
Improving
by 7%
vs 3-y average of 5.3%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
12.3%
=
Operating Income
€22m
/
Revenue
€179.3m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
12.3%
=
Operating Income
$22m
/
Revenue
€179.3m

Peer Comparison

Country Company Market Cap Operating
Margin
ES
Pharma Mar SA
MAD:PHM
1.4B EUR
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
385.9B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
187.6B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
163.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
119.4B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.7B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.4B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.7B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
48.8B USD
Loading...
No Stocks Found

Market Distribution

In line with most companies in Spain
Percentile
51th
Based on 751 companies
51th percentile
12.3%
Low
-2 951.2% — 4.9%
Typical Range
4.9% — 19.6%
High
19.6% — 143.7%
Distribution Statistics
Spain
Min -2 951.2%
30th Percentile 4.9%
Median 12%
70th Percentile 19.6%
Max 143.7%

Pharma Mar SA
Glance View

Market Cap
1.6B USD
Industry
Biotechnology

Nestled in the vibrant biotech landscape of Spain, Pharma Mar SA emerges as a pioneer, weaving the wonders of the sea into groundbreaking medical therapies. Born from the vision of harnessing marine biodiversity, the company delves into the vast oceanic expanse, unearthing bioactive compounds with potential therapeutic uses. This oceanic pursuit forms the backbone of its innovative approach, focusing on oncological drugs derived from the depths of the sea. Their portfolio showcases significant breakthroughs, with products like Yondelis, originally discovered in a sea squirt, reflecting their unique niche in the drug development pipeline. By advancing these marine-based molecules through intensive clinical research, Pharma Mar translates the ocean's secrets into lifesaving treatments, underscoring its hallmark presence in oncology. The company ingeniously monetizes this frontier exploration by orchestrating a business model encompassing rigorous R&D, strategic partnerships, and licensing agreements. Pharma Mar invests heavily in its research, channeling substantial resources into both preclinical and clinical trials to elevate these marine compounds into market-ready drugs. Partnering with global pharmaceutical heavyweights enables them to extend their market reach while sharing development costs and multiplying revenue streams through royalties and milestone payments. Furthermore, licensing their findings expands their financial foothold, allowing them to reap returns on their intellectual exploits without the burden of full-scale commercialization. Pharma Mar’s adept navigation of the pharmaceutical seas has thus firmly anchored its place within the global biotech arena.

PHMMF Intrinsic Value
104.04 USD
Undervaluation 13%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
12.3%
=
Operating Income
€22m
/
Revenue
€179.3m
What is Pharma Mar SA's current Operating Margin?

The current Operating Margin for Pharma Mar SA is 12.3%, which is above its 3-year median of 5.3%.

How has Operating Margin changed over time?

Over the last 3 years, Pharma Mar SA’s Operating Margin has decreased from 34.4% to 12.3%. During this period, it reached a low of -6.2% on Jun 30, 2024 and a high of 34.4% on Sep 30, 2022.

Back to Top